We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Biopharma

Biopharma

Laura Elizabeth Lansdowne profile page

Managing Editor

at Technology Networks

As managing editor, Laura works with the editorial director to create, inform and maintain the overall editorial strategy for Technology Networks. She oversees the in-house editorial team and works directly with commissioned writers to produce content across the publication’s communities. After obtaining a first-class honors degree in biology, Laura worked as a quality assurance technologist before joining the Wellcome Sanger Institute and undertaking an additional qualification in clinical chemistry. In 2015, she left to pursue pharmaceutical and editorial-based roles, before joining Technology Networks in 2017.

Education

University of Kent

Nottingham Trent University

Writtle University College

Chartered Institute of Editing and Proofreading

Accreditations

Biology, BSc (Hons) recognised by The University of Kent

Areas of Expertise

Drug Screening Strategies

Pharmaceutical Development

Molecular & Cellular Biology

People Management

Science Communication

Digital Publishing

Got a Question for Laura Elizabeth Lansdowne?

Get in touch using the contact form linked here and we'll get back to you shortly.

Content Written By, Reviewed By, or Featuring Laura Elizabeth Lansdowne

Total: 472

People sitting in rows within a conference room, all looking toward the presentation.

Why Startups Should Apply to Innovation AveNEW

Former Innovation AveNEW participants reveal how the program helped boost visibility, build valuable connections, and drive commercial opportunities—and share advice for startups considering applying this year.

A hologram of an AI chip within a human mind, held between a human hand and a robotic hand.

Where AI Fits in the Future of Drug Development

Experts reviewed how AI is being applied across pharmaceutical development, from drug discovery to clinical trials. AI has already reduced discovery timelines, but higher data quality, access, and regulatory alignment will be critical for success.

Colorful illustration depicting a drug development pipeline, with scattered pills, DNA, and patient icons representing precision medicine.

The Pursuit of Precision in Cancer Drug Development

Dr. David Parkinson, principal of drug discovery at the Ellison Medical Institute, explores how advances in cancer biology, precision medicine, and AI could make drug development more targeted, efficient, and effective.

The Power of Difference in Cancer Research: From People to Cells

Technology Networks spoke with Dr. Chris Bakal about his career path, research into cancer cell shape and metastasis, and his experiences as an LGBTQIA+ scientist in STEMM.

Render of a capsule containing small granules, against a background full of neurons with dendrites branching out.

Industry Insight

Parkinson’s Disease Drug Trial Extended Following Early Findings

Researchers are evaluating GT-02287, an allosteric GCase modulator, in a clinical trial for Parkinson's disease. Early results suggest that targeting lysosomal health may offer an alternative approach to dopamine-focused therapies.

Healthcare illustration of a uterus above an outstretched hand, representing women's health and reproductive care.

Why PCOS Is Now Called PMOS

A global consensus statement renamed PCOS as PMOS. Experts said the change better reflects the condition’s endocrine and metabolic drivers, which may improve diagnosis, risk assessment, and personalized management.

DNA double helix structure with glowing purple lines on a black background.

Industry Insight

Unlocking FFPE Samples for HiFi Sequencing

Technology Networks spoke with PacBio's Amit Patel and Covaris' Greg Endress about how integrated extraction, library preparation, and HiFi sequencing workflows are unlocking new opportunities for cancer genomics using archived FFPE samples.

Microplate held by gloved hand in front of screen displaying sequencing data.

How To Prepare High-Quality Samples for Next-Generation Sequencing

Learn how to improve NGS library preparation, reduce bias, and increase sequencing yield with practical strategies for fragmentation, amplification, and cleanup.

A person who has just given birth holding their newborn baby, covered in blue drapes within a surgical setting.

Epidural During Birth Does Not Increase Risk to Baby

Researchers reviewed NHS Scotland medical records to assess neonatal outcomes in births with and without epidural analgesia. They found no increased risk between the two groups, paving the way for better informed maternity care.

Illustration of a blue drug capsule with multicolored spheres inside, against a digital circuit background with purple halo.

Why Drug Discovery Needs Human-Relevant Models

This article explores how new approach methodologies are transforming drug discovery through human-relevant models, including organoids, organ-on-chip systems, and AI-driven approaches that aim to improve prediction, safety, and efficacy.

Advertisement

Advertisement

Decoratvive background images

Never miss a story

with the Breaking Science News daily newsletter